Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Sequence Towards Remission in Depression (STRIDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01628783
Recruitment Status : Unknown
Verified June 2012 by Jesper Ekelund, Helsinki University.
Recruitment status was:  Recruiting
First Posted : June 27, 2012
Last Update Posted : June 27, 2012
Academy of Finland
Information provided by (Responsible Party):
Jesper Ekelund, Helsinki University

Brief Summary:
In this study the investigators use clinical, biological and imaging markers to develop predictive markers for remission from depression. The investigators compare individuals who have received placebo to individuals who have received 10 mg of escitalopram for one week. In this double-blind, randomized study the investigators a) compare the groups to observe the short-term effects of escitalopram and b) study the predictive value of these observations with respect to remission. Measures include, but are not restricted to, limbic emotional reactivity as assessed by fMRI, emotional processing, emotional memory, autobiographical memory.

Condition or disease Intervention/treatment Phase
Depression Drug: escitalopram 10 mg Drug: Placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Sequence Towards Remission in Depression
Study Start Date : June 2012
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : October 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: Placebo
Microgranular cellulose in gelatine capsules.
Drug: Placebo
once daily

Experimental: Escitalopram 10 mg
Escitalopram in gelatine capsule
Drug: escitalopram 10 mg
orally once daily

Primary Outcome Measures :
  1. Montgomery-Åsberg rating scale [ Time Frame: 7 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Major depressive disorder with current major depressive episode according to a SCID-I/P interview
  • Montgomery-Åsberg depression rating score 15-30
  • Age 18-60

Exclusion Criteria:

  • Borderline, schizoid or schizotypal personality, bipolar or any psychotic disorder
  • Primary diagnosis is anxiety disorder: 300.00, .01, .02, .21, .22, .29, .23, .3, 309.81, 308.3, 293.89
  • Significant current suicidal ideation, or history of a suicide attempt
  • Lifetime substance dependence; Last-year substance abuse; Last month over 24/16 standard doses of alcohol/week; Lifetime use of illicit substances > x5; Any illicit substance use in last month
  • Depressive disorder due to medical condition or chemical substance
  • Antidepressant medication use in last 4 months
  • Severe, unstable somatic illness
  • Use of antipsychotics, mood stabilizers, systemic corticosteroids, β-blockers or daytime benzodiazepines (a small dose of ≤10mg zolpidem once daily is permissible)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01628783

Layout table for location contacts
Contact: Jesper Ekelund, MD-PhD +358503317987
Contact: Erkki Isometsa, MD-PhD +35894711

Layout table for location information
Helsinki University Central Hospital, Psychiatry Centre Recruiting
Helsinki, Finland, 00029
Contact: Jesper Ekelund, MD-PhD    +358503317987   
Contact: Emma Komulainen, MD    +358465260387   
Sponsors and Collaborators
Jesper Ekelund
Academy of Finland
Layout table for investigator information
Principal Investigator: Erkki Isometsä, MD-PhD Helsinki University
Principal Investigator: Jesper Ekelund, MD-PhD Helsinki University

Layout table for additonal information
Responsible Party: Jesper Ekelund, Professor of Psychiatry, Helsinki University Identifier: NCT01628783    
Other Study ID Numbers: 2012-002476-14
First Posted: June 27, 2012    Key Record Dates
Last Update Posted: June 27, 2012
Last Verified: June 2012
Keywords provided by Jesper Ekelund, Helsinki University:
emotional processing
autobiographic memory
moderator of treatment response
mediator of treatment response
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents